ALSO NOTED: User error hikes risk of insulin pumps in teens; Pfizer preps new promos for Chantix;

> Teens using insulin pumps to control their diabetes run the risk of injury and death, the FDA said, partly because of device malfunction but partly because the children were careless in using them; parents need to carefully watch their children's pump usage, the agency advised. Report

> Pfizer is readying a new ad push for its stop-smoking drug Chantix; the new ads mention warnings about potential suicidal thinking or behavior, prompted by hundreds of reports from Chantix patients. Report

> Three workers died Monday in an explosion at Wockhardt's plant in Ankleshwar, India, an FDA-approved facility that makes cephalosporin. Report

> More than half the 28 experts working on the next edition of the Diagnostic and Statistical Manual of Mental Disorders--the DSM-V--have ties to the drug industry, according to the Center for Science in the Public Interest. Report

> Insurers are heavily pushing "step therapy" to keep drug costs down; doctors are not amused. Report

> Bayer-Schering Pharma won approval to market its low-dose contraceptive YAZ in Europe. Report

> Drug wholesaler McKesson boosted fourth-quarter profits by 19 percent to $307 million on a 9 percent hike in revenues to $26.23 billion. Report

> Prices of prescription drugs can vary by $100 or more from store to store, even within the same chain, a new survey finds. Report

> Minority shareholders in Belgium's Omega Pharma questioned the appointment of Marc Coucke to CEO and criticized his pay package; Coucke owns 30 percent of the pharma's shares. Report

> Generics giants Teva Pharmaceutical Industries posted a lower first-quarter profit, hurt by charges related to its acquisition of CoGenesys, but adjusted earnings grew 52 percent, topping Wall Street estimates. Report

> Business-data firm Thomson posits a link between drugmakers' patent filings and their stock prices. Report

> Discovery Laboratories is signaling investors to hang on for a few more weeks after seeing its stock price go into meltdown mode Friday on the FDA's third approvable letter for Surfaxin. Discovery report

> After spending $175 million in an unsuccessful effort to push a new anthrax vaccine into the clinic, VaxGen has sold the program to Emergent BioSolutions for $2 million. VaxGen report

> After getting squashed in Pfizer's restructuring crunch, Esperion Therapeutics is reopening this week. Report

> FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in general anesthetics. Eisai report

And Finally... Five doctors were convinced a patient had Parkinson's--until another realized he should test her lithium levels. Report

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.